Skip to main content

Advertisement

Table 1 Clinical characteristics of test and control groups of patients

From: Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

  Test group Control group P value
n %    n %   
Age [mean (range)] 61 (38–80)     64 (41–80)     1
Sex          0.059
 Male 31 96.2    18 75.0    
 Female 2 3.8    6 25.0    
Performance status          0.444
 0 1 3.0    0 0    
 1 32 97.0    19 79.2    
 ND      5 20.8    
Smoking history          0.912
 Current smoker 11 33.3    9 37.5    
 Former smoker 21 63.6    14 58.3    
 Never smoker 1 3.0    1 4.2    
Primary site          0.952
 Oral cavity 7 21.2    6 25.0    
 Oropharynx 7 21.2    4 16.7    
 Hypopharynx 6 18.2    4 16.7    
 Larynx 12 36.4    10 41.7    
 ND 1 3.0        
Failure sites          
 Locoregional 28 87.5    NA     
 Distance 19 59.4    NA     
 Both 10 31.3    NA     
Therapeutic regimen    Lengtha Follow-upb    Lengtha Follow-upb  
 Cetuximab 15 45.5 4–64 (12) 15–76 (30) NA     
 Cetuximab/platinum/5FU 13 39.4 4–56 (22) 6–74 (33) NA     
 Cetuximab/taxane 5 15.1 20–32 (24) 24–26 (25) NA     
 Chemotherapy (CDDP) NA     5 20.8 3 (3) 9–121 (40)  
 No chemotherapy      13 54.2    
 ND      6 25    
Skin toxicity
 Rash grade 1 7 21.2    NA     
 Rash grade 2 11 33.3    NA     
 Rash grade 3 5 15.2    NA     
 ND 10 30.3        
Hypomagnesemia
 Yes 6 18.2        
 No 15 45.5        
 ND 12 36.4    24     
  1. NA not applicable, ND no data available
  2. aCycles, range (median)
  3. bMonths, range (median)